SAN FRANCISCO, California and VANCOUVER, Canada, April 26,
2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the
"Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company
focused on developing novel therapies for the treatment of prostate
cancer, today announced that the Company will be presenting at the
2022 Bloom Burton & Co. Healthcare Investor Conference on
Monday, May 2, 2022 at 2:30 p.m. Eastern Time.
David. R. Parkinson, President and Chief Executive Officer of
ESSA Pharma, will participate in and host one-on-one meetings.
Peter Virsik, ESSA's Chief Operating
Officer, and David S. Wood, ESSA's
Chief Financial Officer, will also be participating in the
Monday, May 2,
2:30 p.m. ET
About the Bloom Burton & Co.
Healthcare Investor Conference
The Bloom Burton & Co. Healthcare Investor Conference brings
together U.S., Canadian and international investors who are
interested in the latest developments in the
Canadian healthcare sector. Attendees will have an opportunity
to obtain corporate updates from the premier Canadian publicly
traded and private companies through presentations and private
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer. For more information, please visit
www.essapharma.com and follow us on Twitter under
A webcast of the presentation can be accessed in the
Investors/Events & Presentations section of ESSA's website at
www.essapharma.com. Following the presentation, the webcast will be
archived for 90 days.
SOURCE ESSA Pharma Inc